[Treatment of hyperlipoproteinaemia types IIa, IIb, IV and V with a combination of clofibrate and inositol nicotinate (author's transl)].
Treatment of 14 patients over eight weeks with a combined preparation containing 250 mg clofibrate and 180 mg inositol nicotinate resulted in a decrease of serum-cholesterol level of 20% and of serum triglyceride levels of 40%. The same effect was obtained in 22 patients by clofibrate alone in double doses. There was no significant difference in effect between the two preparations. Doubling the dose of the combined preparation in ten patients did not increase the lipid-lowering effect. After the combined preparation had been stopped triglycerides rose more slowly than after stopping clofibrate alone. There was no difference with regard to the rise in the cholesterol levels. The combined preparation lowered serum lipids regardless of the type of hyperlipoproteinaemia, but the extent was less with types IIa and IIb (n =15) because of the lower initial value, than in those with types IV (n = 26) and V (n = 3).
D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000145:classification / Q000188:drug therapy*; D007294:Inositol; D008297:Male; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D009539:Nicotinic Acids; D014280:Triglycerides; D007294:Inositol; D002784:Cholesterol; D002994:Clofibrate
Behandlung der Hyperlipoproteinämie-Typen IIa, IIb, IV und V mit einer Clofibrat-Inositolnicotinat-Kombination. Ergebnisse einer Dreiphasenstudie